Selva Therapeutics
“Cal Innovation Fund has been a great partner because they put in sweat equity. They have helped source leads and make introductions to help drive growth.”
—Ted Daley, CEO and Co-Founder
Co-founded by Ted Daley, Selva Therapeutics is biotechnology company committed to developing therapeutics for infectious diseases. The company's lead drug candidate, SLV213, is a groundbreaking small molecule antiviral therapy that has demonstrated activity against a wide range of viruses that pose a threat to global health, including the coronavirus that causes COVID-19.
By advancing the development of SLV213, Selva Therapeutics is working towards bringing a much-needed treatment to the market that has the potential to combat multiple life-threatening infectious diseases and safeguard global health.